tetano
Editor, Senior Moderator
Euro Surveill. 2018 Feb;23(7). doi: 10.2807/1560-7917.ES.2018.23.7.18-00057.
[h=1]Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18.[/h] Castilla J[SUP]1,[/SUP][SUP]2[/SUP], Navascu?s A[SUP]3[/SUP], Casado I[SUP]1,[/SUP][SUP]2[/SUP], P?rez-Garc?a A[SUP]3,[/SUP][SUP]1[/SUP], Aguinaga A[SUP]3[/SUP], Ezpeleta G[SUP]2[/SUP], Pozo F[SUP]4[/SUP], Ezpeleta C[SUP]3[/SUP], Mart?nez-Baz I[SUP]1,[/SUP][SUP]2[/SUP], Primary Health Care Sentinel Network[SUP]5[/SUP], Network For Influenza Surveillance In Hospitals Of Navarre[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The 2017/18 interim estimate of trivalent influenza vaccine effectiveness (VE) was 39% (95% confidence interval: 20-54) in Navarre. Compared with individuals unvaccinated in the current and five previous seasons, VE against influenza B was 41% for current and any prior doses, 67% for current vaccination only, and 22% for any prior doses, and 43%, 51% and 54%, respectively against influenza A(H3N2). This suggests moderate VE despite predominance of lineage mismatched influenza B.
[h=4]KEYWORDS:[/h] case-control study; influenza; influenza vaccine; influenza-like illness; repeated vaccination; vaccine effectiveness
PMID: 29471624 DOI: 10.2807/1560-7917.ES.2018.23.7.18-00057
[h=1]Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18.[/h] Castilla J[SUP]1,[/SUP][SUP]2[/SUP], Navascu?s A[SUP]3[/SUP], Casado I[SUP]1,[/SUP][SUP]2[/SUP], P?rez-Garc?a A[SUP]3,[/SUP][SUP]1[/SUP], Aguinaga A[SUP]3[/SUP], Ezpeleta G[SUP]2[/SUP], Pozo F[SUP]4[/SUP], Ezpeleta C[SUP]3[/SUP], Mart?nez-Baz I[SUP]1,[/SUP][SUP]2[/SUP], Primary Health Care Sentinel Network[SUP]5[/SUP], Network For Influenza Surveillance In Hospitals Of Navarre[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The 2017/18 interim estimate of trivalent influenza vaccine effectiveness (VE) was 39% (95% confidence interval: 20-54) in Navarre. Compared with individuals unvaccinated in the current and five previous seasons, VE against influenza B was 41% for current and any prior doses, 67% for current vaccination only, and 22% for any prior doses, and 43%, 51% and 54%, respectively against influenza A(H3N2). This suggests moderate VE despite predominance of lineage mismatched influenza B.
[h=4]KEYWORDS:[/h] case-control study; influenza; influenza vaccine; influenza-like illness; repeated vaccination; vaccine effectiveness
PMID: 29471624 DOI: 10.2807/1560-7917.ES.2018.23.7.18-00057